Intrinsiqq
Acrivon Therapeutics Inc. logo

Acrivon Therapeutics Inc. Insider Trading

ACRV

Compare
Last 12 months

Insiders bought 115K and sold 46K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market
+69K
3 buys · 15 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
3 / 7
executives and directors
Last open-market buy
Jan 2026
Jan 14, 2026

Get an email when ACRV's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 17No plan
    Katharine Peterson
    Chief Accounting Officer · sold 107 at $1.45
    $155
    0.6% of stake
  • Nov 17No plan
    Mary Miller
    Chief Legal Officer · sold 193 at $1.45
    $280
    0.2% of stake
  • Nov 17No plan
    Erick Gamelin
    Chief Development Officer · sold 416 at $1.45
    $603
    0.8% of stake
  • Nov 17No plan
    Eric Devroe
    Chief Operating Officer · sold 628 at $1.45
    $911
    0.4% of stake
  • Nov 17No plan
    Peter Blume-Jensen
    President and CEO · sold 1,780 at avg $1.45
    3K
    <0.1% of stake
  • Oct 22No plan
    Mary Miller
    Chief Legal Officer · sold 513 at $1.84
    $944
    0.6% of stake
  • Oct 5No plan
    Mary Miller
    Chief Legal Officer · sold 294 at $1.99
    $585
    0.4% of stake
  • Aug 25No plan
    Peter Blume-Jensen
    President and CEO · sold 14,036 at $2.21
    31K
    0.5% of stake
  • Aug 18No plan
    Katharine Peterson
    Chief Accounting Officer · sold 101 at $2.01
    $203
    0.6% of stake
  • Aug 18No plan
    Mary Miller
    Chief Legal Officer · sold 185 at $2.01
    $372
    0.2% of stake
  • Aug 18No plan
    Erick Gamelin
    Chief Development Officer · sold 400 at $2.01
    $804
    0.8% of stake
  • Aug 18No plan
    Eric Devroe
    Chief Operating Officer · sold 604 at $2.01
    1K
    0.4% of stake
  • Aug 18No plan
    Kristina Masson
    EVP - Business Operations · sold 1,713 at avg $2.01
    3K
    <0.1% of stake
  • Aug 4No plan
    Adam D. Levy
    Chief Financial Officer · sold 1,142 at $1.57
    2K
    1.7% of stake
  • Jul 21No plan
    Mary Miller
    Chief Legal Officer · sold 573 at $1.76
    1K
    0.7% of stake
  • Jan 14
    Peter Blume-Jensen
    President and CEO · bought 49,000 at $1.68
    82K
    2.1% of stake
  • Jan 14
    Adam D. Levy
    Chief Financial Officer · bought 8,832 at $1.70
    15K
    73% of stake
  • Jan 13
    Eric Devroe
    Chief Operating Officer · bought 10,000 at $1.72
    17K
    15% of stake
  • Apr 30, 2025 – May 1, 2025No plan
    Perceptive Advisors LLC
    Large holder · sold 736,767 at avg $1.38
    $1.02M
    19% of stake
  • Apr 25, 2025 – Apr 29, 2025No plan
    Perceptive Advisors LLC
    Large holder · sold 1,519,952 at avg $1.81
    $2.74M
    28% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ACRV, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ACRV

CompareIntrinsic value
GNLXGenelux Corp.
$2.17-4.82%10
NRXPNRx Pharmaceuticals, Inc.
$2.15-15.69%14
CUECue Biopharma, Inc.
$4.15-7.78%40
AYTUAytu BioPharma Inc.
$2.66+0.00%34
OMEROmeros Corporation
$13.21-5.71%28
ENTAEnanta Pharmaceuticals Inc.
$7.62-4.51%25
SXTP60 Degrees Pharmaceuticals Inc.
$0.47-6.40%25
NXTSNexentis Technologies Inc.
$1.58-7.06%20

Spot a number that looks wrong? Check it in ACRV's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ACRV

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.